RB1 and lung carcinoma: The benefit of CDK inhibitors may be limited to tumors in which the Rb protein remains WT and functional, and thus, reagents that could target this pathway downstream of Rb might be useful in cancers where Rb is commonly mutated (such as lung cancer).